Airways Disease: Phenotyping Heterogeneity Using Measures of Airway Inflammation

Allergy, Asthma & Clinical Immunology

Christopher E Brightling¹  Salman Siddiqui¹ 

[1]Institute of Lung Health, Leicester, UK

关键词: neutrophil;    inflammation;    eosinophil;    COPD;    asthma;   

Others  :  1083821
DOI  :  10.1186/1710-1492-3-2-60

【 授权许可】

   
2007 Canadian Society of Allergy and Clinical Immunology

【 参考文献 】

• [1]Braman SS: The global burden of asthma. Chest 2006, 130(1 Suppl):4S-12S.
• [2]Lopez AD, Mathers CD, Ezzati M, et al.: Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006, 367:1747-57.
• [3]Lapperre TS, Snoeck-Stroband JB, Gosman MM, et al.: Dissociation of lung function and airway inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004, 170:499-504.
• [4]Rosi E, Scano G: Association of sputum parameters with clinical and functional measurements in asthma. Thorax 2000, 55:235-8.
• [5]Pin I, Gibson PG, Kolendowicz R, et al.: Use of induced sputum cell counts to investigate airway inflammation in asthma. Thorax 1992, 47:25-9.
• [6]Pizzichini E, Pizzichini MM, Leigh R, et al.: Safety of sputum induction. Eur Respir J Suppl 2002, 37:9s-18s.
• [7]Efthimiadis A, Spanevello A, Hamid Q, et al.: Methods of sputum processing for cell counts, immunocytochemistry and in situ hybridisation. Eur Respir J Suppl 2002, 37:19s-23s.
• [8]Juniper EF, Kline PA, Vanzieleghem MA, et al.: Long-term effects of budesonide on airway responsiveness and clinical asthma severity in inhaled steroid-dependent asthmatics. Eur Respir J 1990, 3:1122-7.
• [9]Juniper EF, Kline PA, Vanzieleghem MA, et al.: Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in nonsteroid-dependent asthmatics. Am Rev Respir Dis 1990, 142:832-6.
• [10]Haahtela T, Jarvinen M, Kava T, et al.: Comparison of a beta 2- agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med 1991, 325:388-92.
• [11]Adams NP, Bestall JB, Malouf R, et al.: Inhaled beclomethasone versus placebo for chronic asthma. Cochrane Database Syst Rev 2005, (1):CD002738.
• [12]Alsaeedi A, Sin DD, McAlister FA: The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials. Am J Med 2002, 113:59-65.
• [13]Man SF, Sin DD: Inhaled corticosteroids in chronic obstructive pulmonary disease: is there a clinical benefit? Drugs 2005, 65:579-91.
• [14]Beasley R: The burden of asthma with specific reference to the United States. J Allergy Clin Immunol 2002, 109(5 Suppl):S482-9.
• [15]Mortimer KJ, Tata LJ, Smith CJ, et al.: Oral and inhaled corticosteroids and adrenal insufficiency: a case-control study. Thorax 2006, 61:405-8.
• [16]Mortimer KJ, Harrison TW, Tattersfield AE: Effects of inhaled corticosteroids on bone. Ann Allergy Asthma Immunol 2005, 94:15-21.
• [17]Meijer RJ, Postma DS, Kauffman HF, et al.: Accuracy of eosinophils and eosinophil cationic protein to predict steroid improvement in asthma. Clin Exp Allergy 2002, 32:1096-103.
• [18]Pavord ID, Brightling CE, Woltmann G, Wardlaw AJ: Noneosinophilic corticosteroid unresponsive asthma. Lancet 1999, 353:2213-4.
• [19]Little SA, Chalmers GW, MacLeod KJ, et al.: Non-invasive markers of airway inflammation as predictors of oral steroid responsiveness in asthma. Thorax 2000, 55:232-4.
• [20]ten Brinke A, Zwinderman AH, Sterk PJ, et al.: "Refractory" eosinophilic airway inflammation in severe asthma: effect of parenteral corticosteroids. Am J Respir Crit Care Med 2004, 170:601-5.
• [21]Pizzichini E, Pizzichini MM, Gibson P, et al.: Sputum eosinophilia predicts benefit from prednisone in smokers with chronic obstructive bronchitis. Am J Respir Crit Care Med 1998, 158(5 Pt 1):1511-7.
• [22]Brightling CE, Monteiro W, Ward R, et al.: Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2000, 356:1480-5.
• [23]Brightling CE, McKenna S, Hargadon B, et al.: Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease. Thorax 2005, 60:193-8.
• [24]Leigh R, Pizzichini MM, Morris MM, et al.: Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment. Eur Respir J 2006, 27:964-71.
• [25]Leuppi JD, Salome CM, Jenkins CR, et al.: Predictive markers of asthma exacerbation during stepwise dose reduction of inhaled corticosteroids. Am J Respir Crit Care Med 2001, 163:406-12.
• [26]Jatakanon A, Lim S, Barnes PJ: Changes in sputum eosinophils predict loss of asthma control. Am J Respir Crit Care Med 2000, 161:64-72.
• [27]Pizzichini MM, Pizzichini E, Clelland L, et al.: Prednisone-dependent asthma: inflammatory indices in induced sputum. Eur Respir J 1999, 13:15-21.
• [28]Green RH, Brightling CE, McKenna S, et al.: Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002, 360:1715-21.
• [29]Jayaram L, Pizzichini MM, Cook RJ, et al.: Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. Eur Respir J 2006, 27:483-94.
• [30]Chlumsky J, Striz I, Terl M, Vondracek J: Strategy aimed at reduction of sputum eosinophils decreases exacerbation rate in patients with asthma. J Int Med Res 2006, 34:129-39.
• [31]O'Shaughnessy TC, Ansari TW, Barnes NC, Jeffery PK: Inflammation in bronchial biopsies of subjects with chronic bronchitis: inverse relationship of CD8+ T lymphocytes with FEV1. Am J Respir Crit Care Med 1997, 155:852-7.
• [32]Saetta M, Di Stefano A, Turato G, et al.: CD8+ T-lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998, 157(3 Pt 1):822-6.
• [33]Saetta M, Di Stefano A, Maestrelli P, et al.: Airway eosinophilia in chronic bronchitis during exacerbations. Am J Respir Crit Care Med 1994, 150(6 Pt 1):1646-52.
• [34]Confalonieri M, Mainardi E, Della PR, et al.: Inhaled corticosteroids reduce neutrophilic bronchial inflammation in patients with chronic obstructive pulmonary disease. Thorax 1998, 53:583-5.
• [35]O'Donnell RA, Peebles C, Ward JA, et al.: Relationship between peripheral airway dysfunction, airway obstruction, and neutrophilic inflammation in COPD. Thorax 2004, 59:837-42.
• [36]Boschetto P, Quintavalle S, Zeni E, et al.: Association between markers of emphysema and more severe chronic obstructive pulmonary disease. Thorax 2006, 61:1037-42.
• [37]Siva R, Green R, Brightling CE, et al.: Modulation of eosinophilic airway inflammation in COPD. Eur Respir J 2005, 26(Suppl 49):441s.
• [38]O'Donnell RA, Frew AJ: Is there more than one inflammatory phenotype in asthma? Thorax 2002, 57:566-8.
• [39]Douwes J, Gibson P, Pekkanen J, Pearce N: Non-eosinophilic asthma: importance and possible mechanisms. Thorax 2002, 57:643-8.
• [40]Gibson PG, Simpson JL, Saltos N: Heterogeneity of airway inflammation in persistent asthma: evidence of neutrophilic inflammation and increased sputum interleukin-8. Chest 2001, 119:1329-36.
• [41]Wenzel SE, Schwartz LB, Langmack EL, et al.: Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med 1999, 160:1001-8.
• [42]Godon P, Boulet LP, Malo JL, et al.: Assessment and evaluation of symptomatic steroid-naive asthmatics without sputum eosinophilia and their response to inhaled corticosteroids. Eur Respir J 2002, 20:1364-9.
• [43]Berry MA, Morgan A, Green RH, et al.: Clinical and pathological features on non-eosinophilic asthma: a distinct asthma phenotype associated with corticosteroid resistance. Thorax 2005, 60(Suppl 2):ii4.
• [44]Brightling CE, Bradding P, Symon FA, et al.: Mast-cell infiltration of airway smooth muscle in asthma. N Engl J Med 2002, 346:1699-705.
• [45]Chalmers GW, MacLeod KJ, Little SA, et al.: Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma. Thorax 2002, 57:226-30.
• [46]Simpson JL, Scott R, Boyle MJ, Gibson PG: Inflammatory subtypes in asthma: assessment and identification using induced sputum. Respirology 2006, 11:54-61.
• [47]Turner MO, Hussack P, Sears MR, et al.: Exacerbations of asthma without sputum eosinophilia. Thorax 1995, 50:1057-61.
• [48]Anees W, Huggins V, Pavord ID, et al.: Occupational asthma due to low molecular weight agents: eosinophilic and non-eosinophilic variants. Thorax 2002, 57:231-6.
• [49]Belda J, Leigh R, Parameswaran K, et al.: Induced sputum cell counts in healthy adults. Am J Respir Crit Care Med 2000, 161(2 Pt 1):475-8.
• [50]Thomas RA, Green RH, Brightling CE, et al.: The influence of age on induced sputum differential cell counts in normal subjects. Chest 2004, 126:1811-4.
• [51]Chalmers GW, MacLeod KJ, Thomson L, et al.: Smoking and airway inflammation in patients with mild asthma. Chest 2001, 120:1917-22.
• [52]Sagel SD, Kapsner R, Osberg I, et al.: Airway inflammation in children with cystic fibrosis and healthy children assessed by sputum induction. Am J Respir Crit Care Med 2001, 164(8 Pt 1):1425-31.
• [53]Nightingale JA, Rogers DF, Hart LA, et al.: Effect of inhaled endotoxin on induced sputum in normal, atopic, and atopic asthmatic subjects. Thorax 1998, 53:563-71.
• [54]Simpson JL, Scott RJ, Boyle MJ, Gibson PG: Differential proteolytic enzyme activity in eosinophilic and neutrophilic asthma. Am J Respir Crit Care Med 2005, 172:559-65.
• [55]Simpson JL, Grissell TV, Douwes J, et al.: Innate immune activation in neutrophilic asthma and bronchiectasis. Thorax 2007, 62:211-8.
• [56]Chaudhuri R, Livingston E, McMahon AD, et al.: Effects of smoking cessation on lung function and airway inflammation in smokers with asthma. Am J Respir Crit Care Med 2006, 174:127-33.
• [57]Peleman RA, Rytila PH, Kips JC, et al.: The cellular composition of induced sputum in chronic obstructive pulmonary disease. Eur Respir J 1999, 13:839-43.
• [58]Turato G, Di Stefano A, Maestrelli P, et al.: Effect of smoking cessation on airway inflammation in chronic bronchitis. Am J Respir Crit Care Med 1995, 152(4 Pt 1):1262-7.
• [59]Keatings VM, Collins PD, Scott DM, Barnes PJ: Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med 1996, 153:530-4.
• [60]Beeh KM, Beier J, Kornmann O, et al.: Long-term repeatability of induced sputum cells and inflammatory markers in stable, moderately severe COPD. Chest 2003, 123:778-83.
• [61]Rutgers SR, Postma DS, ten Hacken NH, et al.: Ongoing airway inflammation in patients with COPD who do not currently smoke. Chest 2000, 117(5 Suppl 1):262S.
• [62]Tamaoki J: The effects of macrolides on inflammatory cells. Chest 2004, 125(2 Suppl):41S-50S.
• [63]Basyigit I, Yildiz F, Ozkara SK, et al.: The effect of clarithromycin on inflammatory markers in chronic obstructive pulmonary disease: preliminary data. Ann Pharmacother 2004, 38:1400-5.
• [64]Hogg JC, Chu F, Utokaparch S, et al.: The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004, 350:2645-53.
• [65]Pesci A, Majori M, Cuomo A, et al.: Neutrophils infiltrating bronchial epithelium in chronic obstructive pulmonary disease. Respir Med 1998, 92:863-70.
• [66]Baraldo S, Turato G, Badin C, et al.: Neutrophilic infiltration within the ASM in patients with COPD. Thorax 2004, 59:308-12.
• [67]Stanescu D, Sanna A, Veriter C, et al.: Airways obstruction, chronic expectoration, and rapid decline of FEV1 in smokers are associated with increased levels of sputum neutrophils. Thorax 1996, 51:267-71.
• [68]Culpitt SV, Maziak W, Loukidis S, et al.: Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999, 160(5 Pt 1):1635-9.
• [69]Keatings VM, Jatakanon A, Worsdell YM, Barnes PJ: Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med 1997, 155:542-8.
• [70]Sethi S, Maloney J, Grove L, et al.: Airway inflammation and bronchial bacterial colonization in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006, 173:991-8.
• [71]Hatzelmann A, Schudt C: Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther 2001, 297:267-79.
• [72]Bundschuh DS, Eltze M, Barsig J, et al.: In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. J Pharmacol Exp Ther 2001, 297:280-90.
• [73]Spoelstra FM, Berends C, Dijkhuizen B, et al.: Effect of theophylline on CD11b and L-selectin expression and density of eosinophils and neutrophils in vitro. Eur Respir J 1998, 12:585-91.
• [74]Au BT, Teixeira MM, Collins PD, Williams TJ: Effect of PDE4 inhibitors on zymosan-induced IL-8 release from human neutrophils: synergism with prostanoids and salbutamol. Br J Pharmacol 1998, 123:1260-6.
• [75]Cortijo J, Villagrasa V, Navarrete C, et al.: Effects of SCA40 on human isolated bronchus and human polymorphonuclear leukocytes: comparison with rolipram, SKF94120 and levcromakalim. Br J Pharmacol 1996, 119:99-106.
• [76]Rabe KF, Bateman ED, O'Donnell D, et al.: Roflumilast--an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2005, 366:563-71.
• [77]Rennard SI, Schachter N, Strek M, et al.: Cilomilast for COPD: results of a 6-month, placebo-controlled study. Chest 2006, 129:56-66.
• [78]Gamble E, Grootendorst DC, Brightling CE, et al.: Anti-inflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003, 168:976-82.
• [79]Banerjee D, Honeybourne D, Khair OA: The effect of oral clarithromycin on bronchial airway inflammation in moderate-to-severe stable COPD: a randomized controlled trial. Treat Respir Med 2004, 3:59-65.
• [80]Kharitonov SA, Yates D, Robbins RA, et al.: Increased nitric oxide in exhaled air of asthmatic patients. Lancet 1994, 343:133-5.
• [81]Alving K, Weitzberg E, Lundberg JM: Increased amount of nitric oxide in exhaled air of asthmatics. Eur Respir J 1993, 6:1368-70.
• [82]Dupont LJ, Demedts MG, Verleden GM: Prospective evaluation of the validity of exhaled nitric oxide for the diagnosis of asthma. Chest 2003, 123:751-6.
• [83]Berry MA, Shaw DE, Green RH, et al.: The use of exhaled nitric oxide concentration to identify eosinophilic airway inflammation: an observational study in adults with asthma. Clin Exp Allergy 2005, 35:1175-9.
• [84]Payne DN, Adcock IM, Wilson NM, et al.: Relationship between exhaled nitric oxide and mucosal eosinophilic inflammation in children with difficult asthma, after treatment with oral prednisolone. Am J Respir Crit Care Med 2001, 164(8 Pt 1):1376-81.
• [85]Smith AD, Cowan JO, Brassett KP, et al.: Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. N Engl J Med 2005, 352:2163-73.
• [86]Shaw DE, Berry MA, Thomas M, et al.: Asthma exacerbations and exhaled nitric oxide: a randomised controlled trial. Eur Respir J 2006, 28(Suppl 50):572s.
• [87]Pijnenburg MW, Bakker EM, Hop WC, de Jongste JC: Titrating steroids on exhaled nitric oxide in children with asthma: a randomized controlled trial. Am J Respir Crit Care Med 2005, 172:831-6.
• [88]Merkel D, Rist W, Seither P, et al.: Proteomic study of human bronchoalveolar lavage fluids from smokers with chronic obstructive pulmonary disease by combining surface-enhanced laser desorption/ionization-mass spectrometry profiling with mass spectrometric protein identification. Proteomics 2005, 5:2972-80.
• [89]Sloane AJ, Lindner RA, Prasad SS, et al.: Proteomic analysis of sputum from adults and children with cystic fibrosis and from control subjects. Am J Respir Crit Care Med 2005, 172:1416-26.
• [90]Kriegova E, Melle C, Kolek V, et al.: Protein profiles of bronchoalveolar lavage fluid from patients with pulmonary sarcoidosis. Am J Respir Crit Care Med 2006, 173:1145-54.
• [91]Wulfkuhle JD, Liotta LA, Petricoin EF: Proteomic applications for the early detection of cancer. Nat Rev Cancer 2003, 3:267-75.
• [92]Wallace AM, He JQ, Burkett KM, et al.: Contribution of alpha- and beta-defensins to lung function decline and infection in smokers: an association study. Respir Res 2006, 7:76. BioMed Central Full Text
• [93]Nicholson JK, Holmes E, Wilson ID: Gut microorganisms, mammalian metabolism and personalized health care. Nat Rev Microbiol 2005, 3:431-8.
• [94]Nicholson JK, Lindon JC, Holmes E: 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 1999, 29:1181-9.
• [95]Wardlaw AJ, Silverman M, Siva R, et al.: Multi-dimensional phenotyping: towards a new taxonomy for airway disease. Clin Exp Allergy 2005, 35:1254-62.
• [96]Haldar P, Green RH, Berry M, et al.: Categorising the asthma phenotype: results of a factor analysis. Thorax 2006, 60(Suppl 2):ii53.
• [97]Hargreave FE, Parameswaran K Asthma: COPD and bronchitis are just components of airway disease. Eur Respir J 2006, 28:264-7.
• [98]Brightling CE: Clinical applications of induced sputum. Chest 2006, 129:1344-8.